喹硫平与利培酮治疗老年痴呆精神行为症状的临床对照研究  

A Clinical Controlled Study of Quetiapine and Risperidone in the Treatment of Mental and Behavioral Symptoms of Senile Dementia

作　　者：韩翠萍[1] 李雪艳[1] HAN Cuiping;LI Xueyan(Mental Health Center of Zibo(the Fifth People's Hospital of Zibo City),Zibo,Shandong Province,255100 China)

机构地区：[1]山东省淄博市精神卫生中心(淄博市第五人民医院),山东淄博255100

出　　处：《系统医学》2021年第16期23-26,共4页Systems Medicine

基　　金：淄博市重点研发项目(政策引导类项目)(2018kj010051)。

摘　　要：目的讨论喹硫平与利培酮治疗老年痴呆精神行为症状的临床对照研究。方法选择2018年9月—2020年9月收治的120例老年痴呆精神行为症状患者,根据随机数字法分为3组,分别为利培酮组,喹硫平组,联合组。比较3组的简单精神状态检查量表(MMSE评分),痴呆病理行为评定量表(BEHAVE-AD评分),治疗效果,不良反应发生率的情况。结果治疗8周后,联合组的MMSE评分(20.8±5.5)分低于喹硫平组(15.8±5.2)分,利培酮组(14.7±5.2)分,差异有统计学意义(P<0.05)。联合组治疗2周、4周、8周的BEHAVE-AD评分(7.7±3.2)分、(5.7±3.3)分、(4.6±3.1)分低于利培酮组(8.5±3.5)分、(7.2±3.3)分、(5.5±1.9)分,喹硫平组(8.8±4.2)分、(6.7±3.9)分、(5.1±3.6)分,差异有统计学意义(P<0.05)。喹硫平组的治疗效果的75.00%低于联合组的97.50%以及利培酮组的92.50%,差异有统计学意义(P<0.05)。利培酮组的不良反应发生率的70.00%高于联合组的17.50%以及喹硫平组的20.00%,差异有统计学意义(P<0.05)。结论相比单药治疗,喹硫平联合利培酮治疗老年痴呆精神行为症状,可以提高治疗效果,降低不良反应,改善MMSE评分,BEHAVE-AD评分,具有重要的临床价值。Objective To discuss the clinical controlled study of quetiapine and risperidone in the treatment of mental and behavioral symptoms of alzheimer’s disease.Methods From September 2018 to September 2020,120 patients with mental and behavioral symptoms of alzheimer’s disease were selected and divided into three groups according to the random number method,namely risperidone group,quetiapine group,and combination group.The mini mental state examination(MMSE)score,dementia pathological behavior rating scale(BEHAVE-AD)score,treatment effect,and incidence of adverse reactions of the three groups were compared.Results After 8 weeks of treatment,the MMSE score of the combination group(20.8±5.5)points was lower than that of the quetiapine group(15.8±5.2)points and the risperidone group(14.7±5.2)points,and the difference was statistically significant(P<0.05).The BEHAVE-AD score(7.7±3.2)points,(5.7±3.3)points,(4.6±3.1)points of the combined group treatment for 2 weeks,4 weeks,and 8 weeks was lower than that of the risperidone group(8.5±3.5)points,(7.2±3.3)points,(5.5±1.9)points,(8.8±4.2)points,(6.7±3.9)points,(5.1±3.6)points,and the difference was statistically significant(P<0.05).The therapeutic effect of the quetiapine group 75.00%was lower than that of the combination group 97.50%and the risperidone group 92.50%,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the risperidone group 70.00%was higher than that of the combination group 17.50%and the quetiapine group 20.00%,and the difference was statistically significant(P<0.05).Conclusion Compared with single-agent treatment,Quetiapine combined with risperidone in the treatment of mental and behavioral symptoms of Alzheimer’s can improve the treatment effect,reduce adverse reactions,improve MMSE score,BEHAVE-AD score,and have important clinical value.

关 键 词：喹硫平 利培酮 老年痴呆精神行为症状 

分 类 号：R749.16[医药卫生—神经病学与精神病学]